LL-K8-22
LL-K8-22 is a potent, selective and durable PROTAC CDK8-cyclin C dual degrader, with DC50 values of 2.52 and 2.64 μM, respectively. LL-K8-22 also suppresses STAT1 Ser 727 phosphorylation. LL-K8-22 inhibits E2F- and MYC-driven carcinogenic transcriptional programs. LL-K8-22 can be used for triplenegative breast cancer (TNBC) research. (Pink: Ligand for target protein (HY-168683) ; Black: Linker (HY-Y0340) ; Blue: Ligand for E3 ligase (HY-N2427) ) [1].
Product Specifications
CAS Number
[3034487-84-5]
UNSPSC
12352005
Target
CDK; Early 2 Factor (E2F) ; PROTACs; STAT
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; JAK/STAT Signaling; PROTAC; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ll-k8-22.html
Purity
99.76
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(CN1C=C(C2=CC=C(C3=CN=CC4=CC=CC=C43)C=C2)C=N1)N5CCN(CCCC67CC8CC(CC(C8)C7)C6)CC5
Molecular Formula
C37H43N5O
Molecular Weight
573.77
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK8; STAT1
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
LGALS13 (Galactoside-binding soluble lectin 13) BioAssayTM ELISA Kit (Human) discontinued
LGALS13 (Galactoside-binding soluble lectin 13) BioAssayTM ELISA Kit (Human) discontinued
